

# Marcelo J A Amar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6748715/publications.pdf>

Version: 2024-02-01

25  
papers

1,299  
citations

471509

17  
h-index

642732

23  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1737  
citing authors

#	ARTICLE	IF	CITATIONS
1	A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. <i>JAMA Cardiology</i> , 2020, 5, 540.	6.1	259
2	Lecithin: cholesterol acyltransferase “ from biochemistry to role in cardiovascular disease. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2009, 16, 163-171.	2.3	160
3	5A Apolipoprotein Mimetic Peptide Promotes Cholesterol Efflux and Reduces Atherosclerosis in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 334, 634-641.	2.5	103
4	Asymmetry in the Lipid Affinity of Bihelical Amphipathic Peptides. <i>Journal of Biological Chemistry</i> , 2008, 283, 32273-32282.	3.4	87
5	Lecithin Cholesterol Acyltransferase: An Anti- or Pro-atherogenic Factor?. <i>Current Atherosclerosis Reports</i> , 2011, 13, 249-256.	4.8	84
6	5A, an Apolipoprotein A-I Mimetic Peptide, Attenuates the Induction of House Dust Mite-Induced Asthma. <i>Journal of Immunology</i> , 2011, 186, 576-583.	0.8	68
7	HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1203-1215.	1.5	67
8	A dual apolipoprotein C-II mimetic“apolipoprotein C-III antagonist peptide lowers plasma triglycerides. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	56
9	Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents. , 2011, 130, 83-91.		53
10	Human SR-BI and SR-BII Potentiate Lipopolysaccharide-Induced Inflammation and Acute Liver and Kidney Injury in Mice. <i>Journal of Immunology</i> , 2016, 196, 3135-3147.	0.8	50
11	A Novel Apolipoprotein C-II Mimetic Peptide That Activates Lipoprotein Lipase and Decreases Serum Triglycerides in Apolipoprotein E“Knockout Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 227-235.	2.5	48
12	Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. <i>Current Opinion in Investigational Drugs</i> , 2007, 8, 201-12.	2.3	38
13	A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyceridemia and Pancreatitis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1454-1457.	3.6	35
14	Randomized double blind clinical trial on the effect of oral Î±-cyclodextrin on serum lipids. <i>Lipids in Health and Disease</i> , 2016, 15, 115.	3.0	33
15	Dietary Palmitoleic Acid Attenuates Atherosclerosis Progression and Hyperlipidemia in Low“Density Lipoprotein Receptor“Deficient Mice. <i>Molecular Nutrition and Food Research</i> , 2019, 63, e1900120.	3.3	33
16	The Ligand-binding Function of Hepatic Lipase Modulates the Development of Atherosclerosis in Transgenic Mice. <i>Journal of Biological Chemistry</i> , 2004, 279, 45312-45321.	3.4	30
17	Comparison of Omega-3 Eicosapentaenoic Acid Versus Docosahexaenoic Acid-Rich Fish Oil Supplementation on Plasma Lipids and Lipoproteins in Normolipidemic Adults. <i>Nutrients</i> , 2020, 12, 749.	4.1	27
18	Hydrophobic Amino Acids in the Hinge Region of the 5A Apolipoprotein Mimetic Peptide are Essential for Promoting Cholesterol Efflux by the ABCA1 Transporter. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 50-58.	2.5	17

#	ARTICLE	IF	CITATIONS
19	Supplementation with saury oil, a fish oil high in omega-11 monounsaturated fatty acids, improves plasma lipids in healthy subjects. <i>Journal of Clinical Lipidology</i> , 2020, 14, 53-65.e2.	1.5	13
20	Intravenous toxicity and toxicokinetics of an HDL mimetic, Fx-5A peptide complex, in cynomolgus monkeys. <i>Regulatory Toxicology and Pharmacology</i> , 2018, 100, 59-67.	2.7	12
21	Complex association of apolipoprotein E4-containing HDL with coronary artery disease burden in cardiovascular disease. <i>JCI Insight</i> , 2022, 7, .	5.0	10
22	LCAT protects against Lipoprotein X formation in a murine model of drug-induced intrahepatic cholestasis. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00554.	2.4	7
23	A new phenotypic classification system for dyslipidemias based on the standard lipid panel. <i>Lipids in Health and Disease</i> , 2021, 20, 170.	3.0	6
24	Sickle Cell Pulmonary Hypertension and Dysregulated NO Axis in a Mouse Model Are Modulated by Apolipoprotein a-1 Availability. <i>Blood</i> , 2008, 112, 2499-2499.	1.4	0
25	Apolipoprotein A-I Mimetic Peptide and Sickle Vasculopathy: Mouse Model Study of Acute Administration.. <i>Blood</i> , 2009, 114, 1521-1521.	1.4	0